



ASX Release

Acrux 1H FY24 results webinar

Melbourne, Australia; 23 February 2024

Acrux Limited (ASX:ACR, “Acrux” or the “Company”) will host an Investor Webinar where management will present the results for the Company for the half year ended 31 December 2023. Questions that are sent in advance of the webinar to info@acrux.com.au or michael.kotsanis@acrux.com.au will be addressed immediately after the presentation.

Investor Webinar details:

Date: Thursday 29 February 2024

Time: 10:00am Melbourne, Sydney, Canberra, Hobart
9.30am Adelaide
9:00am Brisbane
7:00am Perth
12:00pm New Zealand

Topic: Acrux half year results webinar

Please click on this link to join the webinar:

<https://us02web.zoom.us/j/84147433404>

Or One tap mobile :

+61370182005,,84147433404# Australia

+61731853730,,84147433404# Australia

Other Australian and international numbers are available at:

<https://us02web.zoom.us/j/84147433404>

Webinar ID: 841 4743 3404

Approved for release by the Acrux Board of Directors.



For more information, please contact:

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit www.acrux.com.au